OrthoPediatrics (KIDS) Q4 2025 earnings review
Historic Cash Flow Turnaround Masks Surging G&A
OrthoPediatrics delivered a milestone quarter, generating $9.8M in Free Cash Flow—its first positive FCF quarter in company history. Revenue growth accelerated to 17% YoY, bouncing back from a lumpy Q3, driven by a massive 33% surge in International sales and steady 17% growth in Trauma & Deformity. The pivot from cash burn to cash generation is real, underpinned by a deliberate strategy to slash capital-intensive set deployments. However, the path to sustained profitability is heavily burdened by General & Administrative expenses, which spiked 23% this quarter. FY26 guidance projects an aggressive leap in Adjusted EBITDA to $25M, demanding flawless execution on operating leverage.
🐂 Bull Case
The company successfully reversed its cash-burn trajectory, delivering $9.8M of Free Cash Flow in Q4 and reducing full-year FCF usage by 61%. FY26 guidance calls for FCF breakeven, proving the business model can self-fund.
With major orthopedics players like J&J and Smith & Nephew discontinuing certain pediatric lines, OrthoPediatrics is accelerating market share gains, evident in the 17% growth of its core Trauma & Deformity segment.
🐻 Bear Case
General and administrative expenses are accelerating, jumping 22.6% YoY to $30.0M in Q4, significantly outpacing the 17% revenue growth. This structural cost creep threatens the ambitious FY26 EBITDA targets.
The company remains highly sensitive to the unpredictable timing of 7D capital sales and Latin American distributor stocking orders, which previously caused a sharp deceleration in Q3.
⚖️ Verdict: 🟢
Bullish. The shift to positive free cash flow fundamentally de-risks the investment case. If management can rein in G&A spending, the combination of mid-teens top-line growth and expanding EBITDA margins makes this a compelling growth story.
Key Themes
Set Deployment Strategy Reversing Cash Burn
Management's deliberate strategy to throttle back capital-intensive surgical set deployments is the primary engine behind the cash flow turnaround. Deployments dropped from ~$25M in prior years to $15M in FY25, and guidance indicates a further deceleration to ~$10M in FY26. By increasing the utilization of existing sets (like the 3P platform) rather than constantly building new ones, the company is fundamentally altering its return on invested capital.
OPSB Clinic Expansion Powering Growth
The OrthoPediatrics Specialty Bracing (OPSB) division remains a capital-efficient growth driver. By rapidly expanding its footprint from 26 clinics in early 2024 to over 40 (using a mix of acquisitions and greenfield builds), OPSB is capturing high-margin, non-surgical revenue. This expansion is directly responsible for the sustained double-digit growth in the Trauma & Deformity segment.
Innovation Cycle: 3P Platform & VerteGlide
The product pipeline is accelerating. The launch of the 3P Pediatric Plating Platform (recently adding the Small-Mini System) and the VerteGlide Early Onset Scoliosis (EOS) system are actively displacing legacy systems. Furthermore, the company cited a favorable macro dynamic: as 95% of COGS originate from domestic/Canadian suppliers, they are largely insulated from potential tariff headwinds compared to broad-market peers.
G&A Expense Margin Compression
While gross margins improved (73.2% vs 67.5%), operational leverage was hijacked by a massive 22.6% surge in G&A expenses to $30.0M. Management attributes this to personnel additions for OPSB expansion, stock-based compensation, and depreciation. Until these expenses stabilize, the bottom line remains vulnerable.
Scoliosis Growth Volatility
The Scoliosis segment rebounded to 13% growth in Q4 (up from a dismal 4% in Q3), but this volatility highlights a structural concern: heavy reliance on the unpredictable timing of 7D surgical navigation capital placements. A lack of 7D sales severely limits the pull-through of core implant revenue in any given quarter.
Other KPIs
Accelerating dramatically. Grew 33% YoY, completely rebounding from the sluggish mid-single-digit growth in Q3 caused by Latin American stocking headwinds. This indicates the international distributor model is stabilizing and European adoption is ramping up.
Stable. Up slightly from 72.6% in FY24, despite the mix shift pressures of lower-margin 7D capital sales and international set sales seen earlier in the year. The higher-margin US implant and OPSB volumes are successfully defending the margin profile.
Guidance
Decelerating. The implied 11% to 13% YoY growth rate represents a step down from the 15% growth achieved in FY25. This likely reflects management building in conservatism around international stocking orders and the lumpiness of 7D capital placements.
Accelerating. Implies a massive 69% increase over FY25's $14.8M. Achieving this will require a hard halt to the G&A expense inflation seen in Q4 and relies heavily on increased asset utilization.
Reversing. Following years of heavy cash burn to fund surgical set deployments, the company expects full-year FCF to be neutral. This is structurally supported by the decision to cap FY26 set deployments at ~$10.0M, down from $15.0M in FY25.
Key Questions
G&A Expense Control
G&A grew 23% in Q4, significantly outpacing revenue. How much of this is structural overhead related to the OPSB clinic expansion versus one-time non-cash items, and what is the timeline to see meaningful operating leverage?
7D Capital Visibility
Given the extreme volatility 7D capital sales injected into Q3 and Q4 Scoliosis growth rates, how much 7D contribution is baked into the FY26 guidance of 11-13% overall growth?
Competitor Market Share Capture
With major peers like J&J discontinuing specific pediatric lines, how rapidly are you able to convert those orphaned accounts, and does this require accelerated (and unbudgeted) set deployments to capture?